Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143037 · ClinicalTrials.gov registry record · NA
CM Treatment for Alcohol Dependence Using New Technology
A NA study of Alcohol Use Disorder and Contingency Management, sponsored by UConn Health.
- Completed
- Registry status
- NA
- Development phase
- 114
- Enrollment target
- 2
- Study locations
NCT02143037 is a NA study of Alcohol Use Disorder and Contingency Management that has completed, run by UConn Health. The registered enrollment target is 114 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02143037, a NA study of Alcohol Use Disorder and Contingency Management, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
- 2
- Study locations
Study Summary
Contingency management (CM) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. Importantly, CM interventions that reinforce attendance are more likely to be adopted clinically than those that reinforce abstinence. Having objective indicators of drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based CM treatment in alcohol abusing populations. New technology is now available to gauge alcohol use in patients' natural environments. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) continuously monitors alcohol consumption 24 hours a day. As such, it may be ideal for objective evaluation of alcohol consumption during treatment intervention studies, including those that involve CM. In this study, 114 patients participating in community based outpatient treatment programs for alcohol use disorders will wear SCRAMx for a 12-week period. They will be randomized to standard care or standard care plus CM, with reinforcement contingent upon attendance at treatment. The investigators will assess treatment attendance and alcohol use via SCRAMx and self reports. The investigators expect that patients randomized to the CM intervention will remain in treatment longer and show reductions in both SCRAMx assessed and self reported drinking days relative to those randomized to standard care.
Conditions Studied
Interventions
- BEHAVIORAL usual care
- BEHAVIORAL prize contingency management for attending treatment
Study Locations (2)
Connecticut
- Regional Network of Programs, Inc. - Bridgeport
- Alcohol and Drug Recovery Centers, Inc. - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2013-05 |
| Est. Completion | 2018-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143037
The ClinicalTrials.gov registry entry for NCT02143037 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (65% lower). The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which usual care is the first listed.
NCT02143037 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02143037 about?
NCT02143037 is a clinical study titled "CM Treatment for Alcohol Dependence Using New Technology". Contingency management (CM) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. Importantly, CM interventions that reinforce attendance are more likely to be adopted clinically than those tha...
What is the current status of trial NCT02143037?
This trial is currently completed. It is a NA study. The enrollment target is 114 participants. The study started on 2013-05. Estimated completion is 2018-03.
What conditions does trial NCT02143037 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Contingency Management.
What interventions are being tested in trial NCT02143037?
The interventions under investigation include: usual care (BEHAVIORAL), prize contingency management for attending treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02143037?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02143037 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.